Negative in a 6-assay battery including Ames, chromosome aberration and micronucleus assays
“No genotoxic potential was noted for triclabendazole tested in a battery of 6 genotoxicity in vitro and in vivo assays which include a bacterial reverse mutation assay, chromosome aberration assays, and a micronucleus assay.”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
No fertility effects in rats; not embryotoxic in rat and rabbit EFD studies up to 200 and 20 mg/kg/day
“Orally administered TCBZ did not have effects on fertility in rats. Oral administration of TCBZ was not embryotoxic in rats and rabbits up to 200 and 20 mg/kg/day, which is 1.6 and 0.3 times the clinical dose respectively, based on a body surface area comparison.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗
Safety pharmacology
No stand-alone hERG assay; GLP dog cardiovascular study showed transient QTc prolongation at 100 mg/kg
“A GLP-compliant single-dose cardiovascular study in dogs indicated transient QTc interval prolongation in dogs after dosing with TCBZ at 100 mg/kg which is about 2.5 times the proposed clinical dose based on body surface area comparison.”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗
Genotox: Ames
Negative, with and without metabolic activation
“In the experiments performed without and with microsomal activation, none of the tested concentrations of the drug led to an increase in point mutations in comparison with the negative control.”
✓ VerifiedFDA multi-discipline review, p. 57Source ↗
Genotox: in vitro mammalian
CHO cell cytogenetic (clastogenicity) test: negative
“Under the given experimental conditions, no evidence of clastogenic effects was obtained in CHO cells in vitro treated with TCBZ.”
✓ VerifiedFDA multi-discipline review, p. 59Source ↗
Genotox: in vivo
Micronucleus assay: negative
“No genotoxic potential was noted for triclabendazole tested in a battery of 6 genotoxicity in vitro and in vivo assays which include a bacterial reverse mutation assay, chromosome aberration assays, and a micronucleus assay.”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Carcinogenicity timing
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
hERG / QT
No stand-alone hERG assay; transient QTc prolongation in dogs at 100 mg/kg single dose (~2.5x clinical dose, BSA)
“A GLP-compliant single-dose cardiovascular study in dogs indicated transient QTc interval prolongation in dogs after dosing with TCBZ at 100 mg/kg which is about 2.5 times the proposed clinical dose based on body surface area comparison.”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative